Entinostat (MS-275): Applied Workflows for Cancer and Regenerative Research

Principle Overview: Precision HDAC1/3 Inhibition for Epigenetic Modulation

Entinostat, also known as MS-275 or SNDX-275, is a potent, orally available inhibitor of class I histone deacetylases (HDACs), with high selectivity for HDAC1 (IC50 = 0.368 μM) and HDAC3 (IC50 = 0.501 μM), and substantially lower activity against HDAC8 (IC50 = 63.4 μM) (source: product_spec). By inhibiting these key enzymes, Entinostat increases histone acetylation, leading to relaxed chromatin structures and activation or repression of target genes, thus modulating cell proliferation, apoptosis, and differentiation. Its anti-proliferative efficacy has been demonstrated across a broad range of cancer cell lines, including breast, colon, lung, myeloma, ovary, pancreas, prostate, and leukemia (source: entinostat.net).

Step-by-Step Experimental Workflow Enhancements

Leveraging Entinostat's well-characterized selectivity and pharmacokinetics enables researchers to design robust, reproducible experiments in both cancer and regenerative biology. Below, we outline a typical workflow from reagent preparation to endpoint analysis, spotlighting optimization strategies and critical checkpoints.

• Stock Solution Preparation: Dissolve Entinostat in DMSO (≥18.8 mg/mL) or ethanol (≥7.4 mg/mL with ultrasonic treatment) for optimal solubility. Store aliquots below -20°C and avoid repeated freeze-thaw cycles to maintain potency (source: product_spec).
• Cell Culture Treatment: For cancer cell proliferation inhibition or apoptosis induction in cancer cells, titrate Entinostat across a range (e.g., 0.1–5 μM) depending on cell type and sensitivity. Include vehicle-only controls and, where possible, positive controls such as Trichostatin A (TSA) for benchmarking selective HDAC inhibition (source: isomaltsyn.com).
• Endpoint Readouts: After treatment (24–72 h), assess histone acetylation (e.g., via Western blot for acetyl-H3/H4), cell viability (MTT/XTT/CellTiter-Glo), and apoptosis (Annexin V/PI, caspase activation). For in vivo studies, such as retinoblastoma treatment research, Entinostat dosing should be based on established preclinical models to evaluate tumor burden reduction and tissue acetyl-histone levels (source: entinostat.net).

Protocol Parameters

• HDAC inhibition assay | 0.5 μM Entinostat | in vitro cancer cell lines | Achieves robust HDAC1/3 inhibition with minimal off-target effects | product_spec
• Cell culture incubation | 24–48 hours | cancer cell proliferation/apoptosis assays | Ensures sufficient gene expression changes and phenotypic readouts | workflow_recommendation
• In vivo dosing | 5–10 mg/kg oral gavage, daily | murine solid tumor or retinoblastoma models | Balances efficacy and tolerability in published animal studies | entinostat.net
• Western blot acetyl-histone readout | 10–20 μg total protein/lane | post-treatment samples | Detects global increases in histone acetylation after HDAC inhibition | workflow_recommendation

Key Innovation from the Reference Study

The reference study, Wang et al. (2019), demonstrated that nerve-mediated upregulation of HDAC1 is essential for blastema formation and successful limb regeneration in axolotls. Notably, local administration of Entinostat (MS-275) at amputation sites delayed or inhibited regeneration by suppressing HDAC activity, pinpointing the enzyme’s critical role in early dedifferentiation and tissue patterning. This finding bridges regenerative biology and epigenetic modulation, suggesting that selective HDAC1/3 inhibitors like Entinostat can be used to dissect the timing and cell-type specificity of chromatin remodeling during tissue repair. In practical terms, researchers can now design time-course inhibition assays or spatially restricted delivery protocols to parse the contributions of HDACs in both regeneration and pathological contexts (source: paper).

Advanced Applications & Comparative Advantages

Entinostat’s translational value extends beyond oncology into regenerative research, as highlighted by the axolotl limb model. In cancer systems, its selectivity for HDAC1/3 offers clarity when interpreting anti-proliferative and pro-apoptotic effects (source: romidepsin.org). In solid tumor clinical trials, Entinostat has shown tolerable safety in combination regimens and established recommended phase II doses (source: product_spec). For retinoblastoma treatment research, animal studies demonstrated significant tumor burden reduction and increased acetyl-histone levels in retinal tissue, supporting its utility in ocular oncology (source: entinostat.net).

Comparative analysis with broader-spectrum HDAC inhibitors such as TSA or panobinostat reveals Entinostat's advantage in minimizing off-target effects and toxicity, which is especially important in long-term or developmental studies. Its oral bioavailability further enhances experimental flexibility in in vivo models (source: isomaltsyn.com).

Troubleshooting & Optimization Tips

• Solubility Challenges: Entinostat is insoluble in water; always prepare stock solutions in DMSO or ethanol, using sonication as needed. Filter-sterilize solutions for cell culture use to prevent precipitation (source: product_spec).
• Batch Variability: Use freshly prepared aliquots and avoid repeated freeze-thaw cycles. Monitor compound integrity with LC-MS or HPLC if possible.
• Assay Sensitivity: When assessing cancer cell proliferation inhibition or apoptosis induction, titrate Entinostat concentration carefully and include time-course sampling to capture both early and late phenotypic effects.
• Regenerative Contexts: In tissue regeneration assays, consider spatial (local injection vs. systemic) and temporal (early vs. late) administration to dissect stage-specific HDAC requirements, as demonstrated in axolotl models (source: paper).

Interlinking with Current Literature

This guide complements detailed workflow recommendations from "Precision HDAC1/3 Inhibitor for Cancer and Regeneration", which emphasizes Entinostat’s translational applications in both oncology and regenerative biology. It extends the protocol strategies found in "HDAC1/3 Inhibition for Advanced Cancer Research" by integrating troubleshooting tips and regenerative context. Additionally, our focus on the axolotl regeneration model builds on insights from "Epigenetic Precision in Cancer and Regeneration", offering a direct translation of molecular findings into practical assay design.

Why This Cross-Domain Matters, Maturity, and Limitations

The integration of Entinostat into regenerative biology—exemplified by axolotl limb regeneration research—opens new avenues for dissecting the epigenetic control of tissue repair. While the anti-cancer effects of selective HDAC1/3 inhibition are well-established in preclinical and clinical settings, the reference study's demonstration of context-dependent HDAC1 activity in regeneration underscores the need for careful timing and targeting in experimental design (source: paper). However, translating findings from amphibian models to mammalian or human systems remains a challenge; species-specific differences and tissue microenvironment factors must be accounted for.

Future Outlook: Translational and Therapeutic Implications

The dual role of Entinostat as a research tool in both cancer and regenerative biology is poised for further expansion. Ongoing solid tumor clinical trials and preclinical models in retinoblastoma continue to validate its efficacy and safety, while new studies in tissue regeneration may yield insights into leveraging or modulating epigenetic plasticity for therapeutic benefit. As the field matures, the use of Entinostat (MS-275, SNDX-275) supplied by APExBIO will remain central to high-fidelity, reproducible research in epigenetic modulation (source: product_spec).

To explore detailed protocols and purchase high-quality Entinostat (MS-275, SNDX-275), visit the official product page.